Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MYC S146L is a context-dependent activating substitution in cancer development

ABSTRACT: MYC S146L is a context-dependent activating substitution in cancer development

PROVIDER: PRJNA809750 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18116710_1.fastq.gz	Fastqsanger.gz
	SRR18116710_2.fastq.gz	Fastqsanger.gz
	SRR18116711_1.fastq.gz	Fastqsanger.gz
	SRR18116711_2.fastq.gz	Fastqsanger.gz
	SRR18116712_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 44

Similar Datasets

MYC S146L is a context-dependent activating substitution in cancer development [CUT&TAG]

Project description:MYC S146L is a context-dependent activating substitution in cancer development [CUT&TAG]

| PRJNA809749 | ENA

MYC S146L is a context-dependent activating substitution in cancer development [RNA-seq]

Project description:MYC S146L is a context-dependent activating substitution in cancer development [RNA-seq]

| PRJNA809740 | ENA

MYC S146L is a context-dependent activating substitution in cancer development [RNA-seq]

Project description:MYC is one of the most dysregulated oncogenes and is thought to be fundamental to tumor formation and/or maintenance in many cancer types. This dominant pro-tumor activity makes MYC an attractive target for cancer therapy. However, MYC is a transcription factor lacking enzymatic activity, and the structure of one of its two domains is unknown e.g., its transactivation domain. Consequently, few direct MYC-targeting therapies have been developed, and none have been successful in the clinic. Nevertheless, significant effort has been devoted to understanding the mechanisms of oncogenic MYC activity with the objective of uncovering novel vulnerabilities of MYC-dependent cancers. These extensive investigations have revealed in detail how MYC translocation, amplification, and other upstream perturbations contribute to MYC activity in cancer. However, missense mutations of the MYC gene have remained relatively understudied for their potential role in MYC-mediated oncogenesis. While the function of several low-frequency mutations in MYC have been described, our understanding of other equally or more frequent mutations is incomplete. Herein, we define the function of a recurrent missense mutation in MYC resulting in the substitution S146L. This mutation reinforces the interaction between MYC and its cofactor TRRAP and may enhance oncogenic MYC activity in certain cellular contexts. Implication: our results fortify the mechanistic understanding of oncogenic MYC and may indicate a novel prognostic marker for patients whose tumors harbor the somatic mutation resulting in MYC S146L.

2022-07-31 | GSE197323 | GEO

MYC S146L is a context-dependent activating substitution in cancer development [CUT&TAG]

2022-07-31 | GSE197327 | GEO

S146L in MYC is a context-dependent activating substitution in cancer development.

Project description:MYC is one of the most dysregulated oncogenes and is thought to be fundamental to tumor formation and/or maintenance in many cancer types. This dominant pro-tumor activity makes MYC an attractive target for cancer therapy. However, MYC is a transcription factor lacking enzymatic activity, and the structure of one of its two domains is unknown e.g., its transactivation domain. Consequently, few direct MYC-targeting therapies have been developed, and none have been successful in the clinic. Nevertheless, significant effort has been devoted to understanding the mechanisms of oncogenic MYC activity with the objective of uncovering novel vulnerabilities of MYC-dependent cancers. These extensive investigations have revealed in detail how MYC translocation, amplification, and other upstream perturbations contribute to MYC activity in cancer. However, missense mutations of the MYC gene have remained relatively understudied for their potential role in MYC-mediated oncogenesis. While the function of several low-frequency mutations in MYC have been described, our understanding of other equally or more frequent mutations is incomplete. Herein, we define the function of a recurrent missense mutation in MYC resulting in the substitution S146L. This mutation enhances the interaction between MYC and its cofactor TRRAP and may enhance oncogenic MYC activity in certain cellular contexts.

| S-EPMC9417018 | biostudies-literature

MYC S146L is a context-dependent activating substitution in cancer development

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-07-31 | GSE197330 | GEO

NMT inhibition in the context of MYC levels

Project description:NMT inhibition in the context of MYC levels

| PRJNA645908 | ENA

Gene expression variation in Y-chromosome substitution lines of Drosophila melanogaster

Project description:These arrays were done in the context of a study to probe gene expression variation across Y-chromosome substitution lines of Drosophila melanogaster Keywords: polymorphism, evolution, chromosome substitution

2008-04-30 | GSE9457 | GEO

Gene expression variation in Y-chromosome substitution lines of Drosophila melanogaster

2008-04-29 | E-GEOD-9457 | biostudies-arrayexpress

A sumoylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis

Project description:Myc is an oncogenic transcription factor frequently dysregulated in human cancer. To identify pathways supporting the Myc oncogenic program, we employed a genome-wide RNAi screen for Myc-synthetic-lethal (MySL) genes and uncovered a role for the SUMO-activating-enzyme (SAE1/2). Loss of SAE1/2 enzymatic activity drives synthetic lethality with Myc. Mechanistically, SAE2 inhibition switches a transcriptional subprogram of Myc from activated to repressed. A subset of these SUMOylation-dependent Myc-switchers (SMS genes) governs mitotic spindle function and is required to support the Myc oncogenic program. comparison of 4 treatments: normal HMEC, High Myc in HMEC, SUMO depleted in HMEC, High Myc+Sumo Depleted in HMEC

2011-12-08 | E-GEOD-34055 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data